Asahi Kasei Medical has acquired Virusure Forschung und Entwicklung (ViruSure), an Austrian provider of biosafety testing services.

The acquisition is part of a strategic expansion and reinforcement of Asahi Kasei Medical’s bioprocess business, centered on Planova virus removal filters used in the manufacturing process for biotherapeutics such as plasma derivatives and biopharmaceuticals. It is indicative of Asahi Kasei Medical’s continuing strategic efforts to develop businesses that contribute to the safety of and efficient manufacture of biotherapeutics.

Because biologically derived substances are used in the process of manufacturing biotherapeutics, biosafety tests are required at each step of research, development, and manufacture to prevent harm from viruses or other infectious agents. Driven by strong growth in the biotherapeutics industry, demand for ViruSure’s biosafety testing services and cell banking services thus continues to increase year by year. Such services not only heighten safety but also facilitate the development of pharmaceutical products and contribute to the widespread adoption of high-quality therapies.

By enhancing Asahi Kasei Medical’s ability to provide wide-ranging support to manufacturers of biotherapeutics, including broader services related to bioprocess development and manufacturing, this acquisition expands Asahi Kasei Medical’s sphere of operations and creates new opportunities for further growth. Asahi Kasei Medical will continue to contribute to the safety of biotherapeutics and their efficient manufacture through the provision of innovative and reliable bioprocess products, equipment, and scientific services.